U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN
Oncolytics Biotech Inc. announced that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. food and Drug Administration (FDA) for a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its clinical trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).
The trial is expected to enroll up to 47 patients with metastatic melanoma. This cancer indication was selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill melanoma cells.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.